MedTrace Logo

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

NCT05763121 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1061

Last updated 2025-12-15

No results posted yet for this study

Summary

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.

Conditions

Interventions

DRUG

Dexpramipexole Dihydrochloride

oral administration of dexpramipexole tablet

DRUG

Placebo

oral administration of placebo tablet

Sponsors & Collaborators

  • Areteia Therapeutics

    lead INDUSTRY

Principal Investigators

  • Salman Siddiqui, MD · Imperial College Healthcare NHS Trust (via Imperial Consultants)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2025-12-08
Completion
2025-12-08
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Bulgaria
  • Canada
  • China
  • Colombia
  • Georgia
  • Japan
  • Lebanon
  • Mexico
  • North Macedonia
  • Peru
  • Poland
  • Puerto Rico
  • Romania
  • Serbia
  • South Korea
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05763121 on ClinicalTrials.gov